A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...

What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose? A ...

A study by the University of Barcelona has discovered why the two main types of lung cancer—adenocarcinoma of the lung and ...

Regimen showed benefit in advanced head and neck cancer ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

J&J's Rybrevant and cancer vaccines are showing benefit During the American Society of Clinical Oncology (ASCO) meeting 2026, ...

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

In a phase 3 trial, izalontamab brengitecan shows superiority to chemotherapy in previously treated esophageal squamous cell carcinoma, but questions remain about generalizability outside China.

Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial. This is an ASCO Meeting ...

Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or non­melanoma skin cancer, which is also known as keratinocyte ...